Apixaban and rivaroxaban are both factor Xa inhibitors.
Drugs in the Pipeline
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Findings may help with decision-making in this high-risk patient population.
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.